Pushkal Garg Sells 1,775 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Pushkal Garg sold 1,775 shares of the stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $319.74, for a total value of $567,538.50. Following the sale, the executive vice president directly owned 23,406 shares in the company, valued at $7,483,834.44. This trade represents a 7.05% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Pushkal Garg also recently made the following trade(s):

• On Monday, March 2nd, Pushkal Garg sold 1,717 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $327.66, for a total value of $562,592.22.
• On Friday, February 13th, Pushkal Garg sold 2,242 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $310.08, for a total transaction of $695,199.36.
• On Monday, January 12th, Pushkal Garg sold 1,510 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $362.87, for a total transaction of $547,933.70.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock opened at $320.51 on Friday. The firm’s 50 day simple moving average is $353.84 and its 200 day simple moving average is $415.74. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28. The firm has a market capitalization of $42.51 billion, a PE ratio of 187.43 and a beta of 0.36. Alnylam Pharmaceuticals, Inc. has a 1-year low of $205.87 and a 1-year high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 EPS for the quarter, missing the consensus estimate of $1.43 by ($0.18). The firm had revenue of $1.10 billion during the quarter, compared to the consensus estimate of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The firm’s revenue for the quarter was up 84.9% on a year-over-year basis. During the same period in the previous year, the business earned ($0.65) earnings per share. As a group, analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals News Summary

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Signed a research collaboration with Tenaya Therapeutics to discover and validate genetic targets for cardiovascular disease; the deal includes upfront cash and research funding plus up to $1.13 billion in milestone payments, expanding Alnylam’s RNAi pipeline into a large disease area. Read More.
• Positive Sentiment: Coverage notes a reimbursement win and reported trial progress for Alnylam’s programs — improving near‑term commercial visibility for approved RNAi medicines and supporting revenue upside against current valuation. Read More.
• Positive Sentiment: Industry backdrop remains supportive: market reports project strong growth for orphan drugs, which underpins long‑term demand for Alnylam’s rare‑disease franchises. Read More.
• Neutral Sentiment: Short‑interest figures in recent reports show zero shares and a 0.0 days‑to‑cover — this appears to be a reporting glitch and is unlikely to represent a real change in short positioning.
• Neutral Sentiment: Analyst coverage remains mixed to favorable with a consensus “Moderate Buy” and a wide range of price targets; useful context for longer‑term expectations but not an immediate driver.
• Negative Sentiment: Significant clustered insider selling: CEO Yvonne Greenstreet reported selling ~6,799 shares (~$2.23M) and multiple EVPs sold 1.6k–2.2k shares each across March 2–3. These concurrent executive sales (disclosed in SEC filings and insider summaries) can create short‑term negative sentiment and add selling pressure despite insiders retaining large holdings. Read More. Read More.

Institutional Trading of Alnylam Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. SHP Wealth Management bought a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at about $43,000. Reflection Asset Management purchased a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at about $63,000. Wick Capital Partners LLC purchased a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at about $306,000. Alpine Global Management LLC bought a new position in Alnylam Pharmaceuticals during the 4th quarter worth approximately $820,000. Finally, Anchor Investment Management LLC increased its stake in Alnylam Pharmaceuticals by 19.8% in the 4th quarter. Anchor Investment Management LLC now owns 2,695 shares of the biopharmaceutical company’s stock worth $1,072,000 after purchasing an additional 446 shares during the period. 92.97% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

ALNY has been the subject of several research analyst reports. Wall Street Zen lowered shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 14th. Leerink Partners lowered their price objective on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating on the stock in a research report on Monday, December 15th. HC Wainwright reiterated a “buy” rating and issued a $510.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 18th. Oppenheimer began coverage on Alnylam Pharmaceuticals in a research report on Wednesday, January 7th. They set an “outperform” rating and a $500.00 price target on the stock. Finally, Freedom Capital raised Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, February 17th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $477.96.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.